Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.

PloS one - 1 Jan 2014

van Hemert Formijn J, Berkhout Ben, Zaaijer Hans L

Abstract excerpt

INTRODUCTION: Resistance of the reverse transcriptase (RT) of hepatitis B virus (HBV) to the tenofovir nucleotide drug has not been observed since its introduction for treatment of hepatitis B virus (HBV) infection in 2008. In contrast, frequent viral breakthrough and resistance has been documented for adefovir. Our computational study addresses an inventory of the structural differences between these two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Adenosine Triphosphate
Share to Deoxyguanine Nucleotides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nucleotides

Share to Organophosphonates

Share to RNA-Directed DNA Polymerase

Share to Tenofovir

Share to Thermodynamics

Source

Open in PubMed Open full text

Identifiers

PMID: 25180507
DOI: 10.1371/journal.pone.0106324
PMCID: PMC4152281

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.PMID 25180507Read ↗

Hepatitis B virus resistance to tenofovir: fact or fiction? A synthesis of the evidence to dateSemantic proximity Read ↗

Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanismsSemantic proximity Read ↗

Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations.Semantic proximity Read ↗

Current developments in nucleoside/nucleotide analogues for hepatitis B.Semantic proximity Read ↗

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.Semantic proximity Read ↗

Antiviral therapies: focus on hepatitis B reverse transcriptase.Semantic proximity Read ↗

HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D.Semantic proximity Read ↗

Unraveling the Mechanism of HIV-1 Hypersusceptibility to Tenofovir Imparted by Islatravir Resistance MutationsSemantic proximity Read ↗

Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.Semantic proximity Read ↗

Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment.Semantic proximity Read ↗

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.Semantic proximity Read ↗

Exploring the Drug Resistance of HCV Protease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.